Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness to FVIII in both naive and preimmunized murine hemophilia A setting...
Main Authors: | Allison M Lytle, Harrison C Brown, Na Yoon Paik, Kristopher A Knight, J Fraser Wright, H Trent Spencer, Christopher B Doering |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050116301462 |
Similar Items
-
Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
by: Harrison C Brown, et al.
Published: (2014-01-01) -
Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
by: Sajjad Afraz, et al.
Published: (2022-11-01) -
In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
by: Cansu Hemşinlioğlu, et al.
Published: (2023-06-01) -
Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
by: Louise H Hooimeijer MD, et al.
Published: (2023-03-01) -
Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A
by: Rou Xiao, et al.
Published: (2024-03-01)